EMA: A warning about unusual blood clots with low blood platelets should be added to the product information for Johnson & Johnson's (JNJ) COVID-19 Vaccine Janssen

Market news

20 April 2021

EMA: A warning about unusual blood clots with low blood platelets should be added to the product information for Johnson & Johnson's (JNJ) COVID-19 Vaccine Janssen

These events should be listed as very rare side effects of the vaccine
Overall benefits of COVID-19 Vaccine Janssen in preventing COVID-19 outweigh the risks of side effects

EMA's full release

CAD: Risk skewed for a dovish taper from the BoC and tactical USD/CAD upside - Citi

EUR: Not expecting any change to monetary policy stance nor more clarity on policy framework - Barclays

Market Focus

Material posted here is solely for information purposes and reliance on this may lead to losses. Past performances are not a reliable indicator of future results. Please read our full disclaimer

Open Demo Account & Personal Page

Personal area

support@teletradepartners.com

Risk Warning: Trading in the financial markets (including trading on margin) provides a wide range of opportunities and enables investors ready to take risks to make high profits, but it carries a potentially high level of risk of loss. Therefore, prior to trading you should take into careful consideration whether such operations are suitable for you in terms of your level of knowledge and financial situation.